197 related articles for article (PubMed ID: 19250334)
1. Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys.
Huang LZ; Parameswaran N; Bordia T; Michael McIntosh J; Quik M
J Neurochem; 2009 May; 109(3):826-37. PubMed ID: 19250334
[TBL] [Abstract][Full Text] [Related]
2. Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine.
Bordia T; Parameswaran N; Fan H; Langston JW; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2006 Oct; 319(1):285-92. PubMed ID: 16837557
[TBL] [Abstract][Full Text] [Related]
3. Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage.
McCallum SE; Parameswaran N; Bordia T; McIntosh JM; Grady SR; Quik M
Mol Pharmacol; 2005 Sep; 68(3):737-46. PubMed ID: 15933214
[TBL] [Abstract][Full Text] [Related]
4. Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum.
O'Leary K; Parameswaran N; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2008 May; 325(2):646-54. PubMed ID: 18305015
[TBL] [Abstract][Full Text] [Related]
5. Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.
Quik M; Polonskaya Y; Kulak JM; McIntosh JM
J Neurosci; 2001 Aug; 21(15):5494-500. PubMed ID: 11466420
[TBL] [Abstract][Full Text] [Related]
6. Selective recovery of striatal 125I-alpha-conotoxinmii nicotinic receptors after nigrostriatal damage in monkeys.
Lai A; Sum J; Fan H; McIntosh JM; Quik M
Neuroscience; 2004; 127(2):399-408. PubMed ID: 15262330
[TBL] [Abstract][Full Text] [Related]
7. Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs.
Khwaja M; McCormack A; McIntosh JM; Di Monte DA; Quik M
J Neurochem; 2007 Jan; 100(1):180-90. PubMed ID: 17227438
[TBL] [Abstract][Full Text] [Related]
8. Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum.
Bordia T; Grady SR; McIntosh JM; Quik M
Mol Pharmacol; 2007 Jul; 72(1):52-61. PubMed ID: 17409284
[TBL] [Abstract][Full Text] [Related]
9. The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.
Bordia T; McGregor M; Papke RL; Decker MW; McIntosh JM; Quik M
Exp Neurol; 2015 Jan; 263():277-84. PubMed ID: 25261754
[TBL] [Abstract][Full Text] [Related]
10. α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease.
Perez XA; Bordia T; McIntosh JM; Quik M
Mol Pharmacol; 2010 Nov; 78(5):971-80. PubMed ID: 20732972
[TBL] [Abstract][Full Text] [Related]
11. Loss of nicotinic receptors in monkey striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment is due to a decline in alpha-conotoxin MII sites.
Kulak JM; McIntosh JM; Quik M
Mol Pharmacol; 2002 Jan; 61(1):230-8. PubMed ID: 11752225
[TBL] [Abstract][Full Text] [Related]
12. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
13. Declines in different beta2* nicotinic receptor populations in monkey striatum after nigrostriatal damage.
Kulak JM; Musachio JL; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2002 Nov; 303(2):633-9. PubMed ID: 12388645
[TBL] [Abstract][Full Text] [Related]
14. Chronic nicotine treatment increases nAChRs and microglial expression in monkey substantia nigra after nigrostriatal damage.
Quik M; Campos C; Parameswaran N; Langston JW; McIntosh JM; Yeluashvili M
J Mol Neurosci; 2010 Jan; 40(1-2):105-13. PubMed ID: 19685015
[TBL] [Abstract][Full Text] [Related]
15. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
Quik M; Chen L; Parameswaran N; Xie X; Langston JW; McCallum SE
J Neurosci; 2006 Apr; 26(17):4681-9. PubMed ID: 16641249
[TBL] [Abstract][Full Text] [Related]
16. Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.
Huang LZ; Grady SR; Quik M
J Pharmacol Exp Ther; 2011 Sep; 338(3):932-41. PubMed ID: 21665941
[TBL] [Abstract][Full Text] [Related]
17. Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function.
Perez XA; Bordia T; McIntosh JM; Grady SR; Quik M
Mol Pharmacol; 2008 Sep; 74(3):844-53. PubMed ID: 18583454
[TBL] [Abstract][Full Text] [Related]
18. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
Zhang D; McGregor M; Bordia T; Perez XA; McIntosh JM; Decker MW; Quik M
Mov Disord; 2015 Dec; 30(14):1901-1911. PubMed ID: 26573698
[TBL] [Abstract][Full Text] [Related]
19. The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.
Bordia T; McIntosh JM; Quik M
J Neurochem; 2013 Apr; 125(2):291-302. PubMed ID: 23373725
[TBL] [Abstract][Full Text] [Related]
20. Compensation in pre-synaptic dopaminergic function following nigrostriatal damage in primates.
McCallum SE; Parameswaran N; Perez XA; Bao S; McIntosh JM; Grady SR; Quik M
J Neurochem; 2006 Feb; 96(4):960-72. PubMed ID: 16412097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
